de Jong YP, Uil SM, Grotjohan HP, et al, Isala Klinieken, Zwolle, and University Medical Center Gronigen, the Netherlands. Oral or IV prednisolone in the treatment of COPD exacerbations. A randomized, controlled, double- blind study. Chest. Dec 2007;132:1741-1747.
de Jong YP, Uil SM, Grotjohan HP, et al, Isala Klinieken, Zwolle, and University Medical Center Gronigen, the Netherlands. Oral or IV prednisolone in the treatment of COPD exacerbations. A randomized, controlled, double- blind study. Chest. Dec 2007;132:1741-1747.
Patients who are hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD) are usually given corticosteroids by the intravenous route. However, a study conducted in the Netherlands found that oral corticosteroids are just as effective as intravenous therapy in this setting.
In this study, 210 patients wererandomly assigned to treatment with oral or intravenous prednisolone (60 mg) for 5 days, followed by a gradual tapering of oral prednisolone for a total 11-day course. All patients also received nebulized ipratropium and albuterol, 4 times a day, and oral amoxicillin/clavulanate. The primary outcome measure was treatment failure, which was defined as death, ICU admission, rehospitalization for COPD, or intensification of therapy during 90 days of follow-up.
In the first week, both treatment groups experienced improvement in pulmonary function (as assessed by spirometry) and health-related quality of life, with no significant difference between the groups. The 2 groups did not differ with respectto treatment failure (intravenous therapy, 61.7%; oral therapy, 56.3%) or mean length of hospital stay (11.9 and 11.2 days, respectively).
The authors acknowledge that the overall treatment failure rate in their study was higher than that previously reported (59% vs 37%). This may be because their study used a lower dosage of corticosteroid. Another possible explanation is that the prescription of antibiotics or corticosteroids by general practitioners in the outpatient setting was scored as a treatment failure.
The authors conclude that because oral corticosteroids are more convenient to use and are less expensive, the oral route is preferable for most patients hospitalized with an exacerbation of COPD.
Pavord ID, Cox G, Thomson NC, et al, University Hospitals of Leicester, UK, and other centers. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. Dec 15, 2007; 176:1185-1191.
Bronchial thermoplasty is a procedure designed to improve asthma control by reducing airway smooth muscle. The results of preliminary studies have been encouraging, and now Pavord and associates report that bronchial thermoplasty may be able to achieve long-term improvement in asthma control. However, the downside of this procedure is that it is associated with a short-term worsening of asthma symptoms.
Their study included 32 adults who had severe, persistent asthma that was not adequately controlledby inhaled corticosteroids, long-acting β2-agonists, and other asthma therapies. The participants were randomly assigned to undergo bronchial thermoplasty (15 patients) or to a control group (17 patients). Treatment was followed by a 16-week phase in which corticosteroid therapy was held stable, a 14-week weaning phase, and a 16- week reduced-corticosteroid phase.
Bronchial thermoplasty caused a transient worsening of asthma symptoms. Four of 15 patients who underwent this procedure were hospitalized for respiratory symptoms during the treatment period; most of the hospitalizations occurred within 3 days of treatment. Two of the patients had segmental lobar collapse. There were no hospitalizations in the control group.
At 22 weeks, the patients who underwent bronchial thermoplasty had significantly more improvementin use of rescue medications, prebronchodilator forced expiratory volume in 1 second, and Asthma Control Questionnaire scores than the control group. At 52 weeks, the differences in rescue medication use and the asthma control scores were still significant.
3 Reasons Urology Practices Should Add Onsite UTI PCR Labs Under New LCD Rules
March 11th 20251. ONSITE PCR TESTING BRINGS SIGNIFICANT CLINICAL BENEFITS TO A PRACTICE. - ACCURACY Traditional urine cultures can give false-negative results. - SPECIFICITY Accurate microbial identification leads to targeted treatment. - SPEED Same day results vs. 3-5 days for traditional urine cultures - - - ANTIBIOTIC RESISTANCE MARKERS Improves antimicrobial stewardship 2. MAINTAIN INDEPENDENCE BY INCREASING REVENUE SIGNIFICANTLY THROUGH REVENUE SHIFTING FROM THE REFERENCE LAB TO THE PRACTICE. - Turnkey: Consultation on COLA and CLIA certification, all necessary equipment, standard operating procedures, personnel sourcing and interview, billing and coding training, 3-4 days of onsite training. - Stark Law Compliant: Complies with anti-kickback statutes. - Medicare part B pays at 100%, Med Advantage Plans at 80% - No lab build-out, only 8 linear feet of counter space needed - Z-code procurement for required states 3. BETTER PATIENT CARE LEADS TO BETTER OUTCOMES. - CONVENIENCE Point of care, no third-party referral lab. - TIMELY Results early in the care process. - CORRECT MEDICATION Avoids two trips to the pharmacy. - BETTER OUTCOMES Reduction of recurrent UTI and hospitalizations